Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
Details
Publication Year 2023-03,Volume 22,Issue #1,Page 59-66
Journal Title
Clinical Colorectal Cancer
Publication Type
Research article
Abstract
BACKGROUND: The BRAF inhibitor encorafenib in combination with cetuximab was recently approved for patients with BRAF(V600E)-mutated (BRAF(V600E)mut) metastatic colorectal cancer (mCRC). Approval was based on positive results from the phase 3 BEACON CRC study in BRAF(V600E)mut mCRC patients who had progressed after 1-2 previous regimens. This analysis provides a detailed examination of the adverse events (AEs) of interest (AEIs) with encorafenib+cetuximab in the BEACON study to aid gastrointestinal oncologists, given the limited experience with this combination. MATERIALS AND METHODS: AEIs, including dermatological AEs, arthralgia/myalgia, nausea/vomiting, diarrhea, abdominal pain, fatigue/asthenia and nephrotoxicity, were examined in the doublet therapy group. Clinical characteristics associated with these AEs, AE grade, time to onset and time to resolution were also studied. RESULTS: Safety analysis included 216/220 patients randomized to doublet therapy. The most commonly occurring AEI was dermatological toxicity (75.5%), followed by arthralgia/myalgia (56.0%) and fatigue/asthenia (56.0%). Other than nephrotoxicity (7 patients; 5/7 with Grade 3 or 4), most AEs were Grade 1 or 2. Most AEs were more common in women than men (nausea/vomiting, diarrhea, abdominal pain, dermatological AEs, and arthralgia/myalgia). Nausea/vomiting, abdominal pain and fatigue/asthenia were more common in patients aged >/=70 years. Most AEs developed early, within the first 1-2 months of treatment, and resolved within 1-2 weeks. In addition, survival outcomes were better in patients experiencing arthralgia/myalgia or dermatological toxicities. CONCLUSION: This analysis indicated that, except for rare cases of nephrotoxicity, encorafenib+cetuximab is well tolerated in most patients, with most AEIs being mild-to-moderate in severity, occurring early and resolving rapidly. CLINICAL TRIAL REGISTRATION: the BEACON study (ClinicalTrials.gov, NCT02928224; EudraCT, 2015-005805-35).
Publisher
Elsevier
Keywords
Male; Humans; Female; Cetuximab; *Colorectal Neoplasms/drug therapy/genetics; Asthenia/chemically induced; Proto-Oncogene Proteins B-raf/genetics; Myalgia/chemically induced/drug therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; *Colonic Neoplasms/drug therapy; *Rectal Neoplasms/drug therapy; Vomiting/chemically induced; Nausea/chemically induced; Fatigue/etiology; Mutation; BRAF inhibitors; Biomarkers; Toxicity; enco+cetux; mCRC
Department(s)
Medical Oncology
PubMed ID
36653241
Open Access at Publisher's Site
https://doi.org/10.1016/j.clcc.2022.12.003
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-07-11 06:23:37
Last Modified: 2023-07-11 06:25:37

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙